Brandolini, Micaela and Cattelan, Anna Maria and Orani, Anna and Sighinolfi, Laura and Andreoni, Massimo and Nardini, G. and Sotgiu, Giovanni and Maserati, Renato (2008) Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing. Journal of the International AIDS Society, Vol. 11 (Suppl. 1), P56. ISSN 1758-2652. Article.
We are conducting a multicenter, randomized, controlled, prospective, open trial to evaluate both the efficacy and toxicity of nevirapine (NVP) (given twice [BID] or once daily [QD]) in virologically-suppressed patients on a PIbased HAART. NVP BID dosing is maintained for 2 months after the switch in both groups.
I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore
Repository Staff Only: item control page